EUVIMEDEUVIMED entdecken
Crossref

Manganese dioxide nanoparticles attenuate pathological retinal angiogenesis by inhibiting the PLK1/AKT/FOXO1 signaling axis

Min Zhao, Yong-Xuan Liu iD, Cheng-Yue Ding, Xian-Hui Wu, Zheng Nie, Hui-Min Zhu, Wen Zhou, Hao-Tian Xue iD, Hong-Ying Wang, Ling-Yun Ma, Jia-Wei Zhao, Wei Shen iD

Biomedical Materials · 2026

DOI: 10.1088/1748-605x/aeaa02 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Materials, 2026. Verfasst von Min Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, People's Republic of China. Hauptthemen laut MEDLINE: Manganese Compounds, Oxides, Retinal Neovascularization, Nanoparticles. Die Arbeit nennt 91 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathological retinal neovascularization (RNV) is a primary etiology of irreversible vision loss in debilitating conditions such as diabetic retinopathy and retinal vein occlusion. While metal-oxide nanomaterials have emerged as potent candidates for anti-angiogenic intervention, their clinical translation remains constrained by persistent biosafety concerns and inherent cytotoxicity. Manganese dioxide nanoparticles (MnO 2 NPs), distinguished by their robust enzyme-mimetic activity and microenvironment-responsive properties, have demonstrated substantial therapeutic promise in oncology; however, their specific function and underlying mechanisms in RNV remain largely uncharacterized. This study provides a systematic investigation into the anti-angiogenic potential of MnO 2 NPs and identifies molecular pathways that may underlie their activity, representing a step toward mechanistic proof-of-concept. Our results demonstrate that MnO 2 NPs possess exceptional biocompatibility both in vitro and in vivo . These nanoparticles exert a potent, dose-dependent inhibitory effect on the proliferation, migration, and sprouting of human umbilical vein endothelial cells (HUVECs). Moving to in vivo validation, MnO 2 NPs demonstrate a distinct capacity to modulate physiological retinal vascular development in neonatal mice and, more critically, markedly attenuate pathological neovascularization in an oxygen-induced retinopathy model. Mechanistically, integrated transcriptomic analysis revealed a significant modulation of angiogenesis-related gene clusters, which—along with Western blot validation—confirmed that MnO 2 NPs exert their effects by targeting the PLK1/AKT/FOXO1 signaling axis. In conclusion, MnO 2 NPs emerge as a compelling and innovative therapeutic candidate for managing vision-threatening ocular vascular disorders. These findings not only offer a targeted pharmacological intervention for retinal diseases but also provide a mechanistic blueprint for the rational design of next-generation multifunctional nanomedicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Manganese CompoundsOxidesRetinal NeovascularizationNanoparticlesAnimalsHumansSignal TransductionProto-Oncogene Proteins c-aktForkhead Box Protein O1MiceHuman Umbilical Vein Endothelial CellsProtein Serine-Threonine KinasesCell ProliferationCell Cycle ProteinsCell MovementProto-Oncogene ProteinsMice, Inbred C57BLBiocompatible Materials

Stichwörter der Autor:innen

PLK1-AKT-FOXO1 axisangiogenesismanganese dioxide nanoparticlesoxygen-induced retinopathyretinal neovascularization

Substanzen

Manganese CompoundsOxidesProto-Oncogene Proteins c-aktForkhead Box Protein O1manganese dioxideProtein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsFOXO1 protein, humanBiocompatible Materials

Autor:innen und Institutionen

  • Department of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, People's Republic of China.
  • Department of Stomatology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, People's Republic of China.

ORCID-Profile: Yong-Xuan Liu, Hao-Tian Xue, Wei Shen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhao, M., Liu, Y. X., Ding, C. Y., Wu, X. H., Nie, Z., Zhu, H. M., Zhou, W., Xue, H. T., Wang, H. Y., Ma, L. Y., Zhao, J. W., & Shen, W. (2026). Manganese dioxide nanoparticles attenuate pathological retinal angiogenesis by inhibiting the PLK1/AKT/FOXO1 signaling axis. Biomedical Materials. https://doi.org/10.1088/1748-605x/aeaa02

Vancouver

Zhao M, Liu YX, Ding CY, Wu XH, Nie Z, Zhu HM, et al. Manganese dioxide nanoparticles attenuate pathological retinal angiogenesis by inhibiting the PLK1/AKT/FOXO1 signaling axis. Biomedical Materials. 2026. doi:10.1088/1748-605x/aeaa02

BibTeX
@article{Zhao2026,
  author = {Zhao, Min and Liu, Yong-Xuan and Ding, Cheng-Yue and Wu, Xian-Hui and Nie, Zheng and Zhu, Hui-Min and Zhou, Wen and Xue, Hao-Tian and Wang, Hong-Ying and Ma, Ling-Yun and Zhao, Jia-Wei and Shen, Wei},
  title = {Manganese dioxide nanoparticles attenuate pathological retinal angiogenesis by inhibiting the PLK1/AKT/FOXO1 signaling axis},
  journal = {Biomedical Materials},
  year = {2026},
  doi = {10.1088/1748-605x/aeaa02}
}
Kostenlos starten →